Drugs / ProMetS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02861261 | Aug 2016 → Dec 2017 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT03336840 | Jun 2017 → Mar 2019 | polycystic ovary syndrome | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ProMetS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03336840 ↗ |
| Modality | Other / unclassified | “Probiotics are live bacteria that offer a health benefit to the host when administered in adequate amounts.” NCT03336840 ↗ |
| Route | Oral | “ProMetS probiotics powder administered orally every night” NCT02861261 ↗ |